TheEdgeResearch
Home / Stocks / PHXM

PHAXIAM Therapeutics S.A. (PHXM)

NASDAQ Healthcare Biotechnology
$3.10 ▼ -5.20%
Market Cap
$19.9M
Sector
Healthcare
Industry
Biotechnology
Beta
1.80
52-Wk Range
2.5-13.0
CEO
Eric Soyer
Country
FR
Currency
USD

PHAXIAM Therapeutics S.A. operates in the Biotechnology industry of the Healthcare sector, headquartered in Lyon, FR. The stock last traded at $3.10, down 5.20% on the session, giving a market capitalisation of $19.9M. On trailing twelve-month figures it carries a trailing P/E of -0.61, a net margin of 0.0%. Its beta of 1.80 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-0.61
Price / Sales
0.00
Price / Book
0.56
EV / EBITDA
-0.81
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Return on equity
—
Debt / equity
0.43
Current ratio
1.06
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Capital Market
Employees
49
IPO date
2017-10-26
Headquarters
Lyon, FR
About PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.

Comparable companies

PHAXIAM Therapeutics S.A. is most often compared with the following Healthcare names:

ATONCSCIDOMHELEVKAMEIPMTVANYMXFPIRSTRAW
More research on PHXM
PHXM technical analysis PHXM TheEdge Score Compare against peers
Open full interactive analysis & DCF →